California changes health coverage requirements for antiretroviral products
Oct 4, 2026 edition · GC-2026-0127 · Published 2026-10-04 · Version 2 · Final
SB 1023 requires specified non-self-administered HIV-prevention products to be available under both medical and pharmacy benefits for contracts and policies issued, amended or renewed from January 1, 2027.
What happened
California chaptered SB 1023 on September 26, 2026, changing coverage for FDA-approved antiretroviral drugs, drug devices and drug products used to prevent HIV/AIDS. For affected health plan contracts and health insurance policies issued, amended or renewed on or after January 1, 2027, non-self-administered products must be covered under both medical and prescription drug benefits. A product obtained through the prescription drug benefit must be dispensed and administered by a provider acting within the scope of their license. The contract or policy trigger matters: the chaptered text supplies a future implementation date rather than an October 4 requirement to treat all existing coverage as already changed.
The amended sections also prohibit prior authorization and step therapy for medically necessary HIV-prevention products, including PrEP and PEP, while retaining a therapeutic-equivalent exception if at least one equivalent is available without those restrictions. They preserve coverage for pharmacist-furnished PrEP and PEP, pharmacist services and related testing, with out-of-network payment tied to an out-of-network pharmacy benefit. Specialized dental, mental health or vision coverage and Medicare supplements are excluded. The health plan section also excludes Medi-Cal managed care to the extent these services are outside its contract with the Department of Health Care Services. Benefits teams therefore need to assess the product, benefit channel and particular coverage arrangement rather than apply a single rule to every antiretroviral use or insurance product.
Scope and timing
- Authority status
- Final
- Applicability
- Directly applicable
- Audience
- Health systems, Provider networks
- Jurisdiction
- California
- Recorded date
- 2027-01-01
- Date type
- effective
Why it matters
Plans, insurers, pharmacy benefit managers and dispensing partners need coordinated benefit and administration arrangements so eligible non-self-administered prevention products can be accessed through both channels.
Recommended action
Identify affected contracts and policies at their January 2027 issuance, amendment or renewal trigger. Map HIV-prevention products to medical and pharmacy benefits, confirm licensed dispensing and administration arrangements, and review authorization rules, equivalent options and coverage exclusions.
Sources
- SB 1023, bill historyOfficial · California Legislature · 2026-09-26 · Source review 2026-09-27
- SB1023 chaptered text, retained official rendered documentOfficial · California Legislature · 2026-09-26 · Source review 2026-10-15
- Official Assembly 2023-24 Constitution, Article IV section 8Official · California Legislature · Source review 2026-10-14
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Compliance Sweep report →